Correlation Between SPDR SP and IShares Genomics

Can any of the company-specific risk be diversified away by investing in both SPDR SP and IShares Genomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SPDR SP and IShares Genomics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SPDR SP Pharmaceuticals and iShares Genomics Immunology, you can compare the effects of market volatilities on SPDR SP and IShares Genomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SPDR SP with a short position of IShares Genomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of SPDR SP and IShares Genomics.

Diversification Opportunities for SPDR SP and IShares Genomics

0.5

Correlation Coefficient

SPDR SP  IShares Genomics

Very weak diversification

The 3 months correlation between SPDR and IShares is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding SPDR SP Pharmaceuticals and iShares Genomics Immunology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on iShares Genomics Imm and SPDR SP is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SPDR SP Pharmaceuticals are associated (or correlated) with IShares Genomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of iShares Genomics Imm has no effect on the direction of SPDR SP i.e., SPDR SP and IShares Genomics go up and down completely randomly.

Pair Corralation between SPDR SP and IShares Genomics

Considering the 90-day investment horizon SPDR SP Pharmaceuticals is expected to under-perform the IShares Genomics. But the etf apears to be less risky and, when comparing its historical volatility, SPDR SP Pharmaceuticals is 1.36 times less risky than IShares Genomics. The etf trades about -0.34 of its potential returns per unit of risk. The iShares Genomics Immunology is currently generating about -0.13 of returns per unit of risk over similar time horizon. If you would invest  2,354  in iShares Genomics Immunology on September 23, 2024 and sell it today you would lose (90.00) from holding iShares Genomics Immunology or give up 3.82% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

SPDR SP Pharmaceuticals  vs.  iShares Genomics Immunology

SPDR SP Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days SPDR SP Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, SPDR SP is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

iShares Genomics Imm

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days iShares Genomics Immunology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, IShares Genomics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with SPDR SP and IShares Genomics

The main advantage of trading using opposite SPDR SP and IShares Genomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SPDR SP position performs unexpectedly, IShares Genomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IShares Genomics will offset losses from the drop in IShares Genomics' long position.

The idea behind SPDR SP Pharmaceuticals and iShares Genomics Immunology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.